Avendus Future Leaders Fund invests ₹300 cr in Aragen Life Sciences with SBI Life

Sharing purchase is a secondary transaction, both investors buy more than 2.5%’from Reddy Investment Trust, associated with the GVK group. Güven diligated his shares in Aragen, known as the GVK Biosciences, before the re -brand on behalf of the current name in December 2020.

“Health services have been a secular theme between the funds for a long time. Mint In an interview. The fund aims at late stage companies in all three of the investment instruments.

Aragen Life Sciences, Haydarabad -based contract research, development and manufacturing organization (CRDMO). It provides services such as drug discovery, development and production to other companies in the health and pharmaceutical industry.

AVENDUS FLF III is the latest investor To join Aragen’s Cakitization Table. Chandra said the fund’s strategy did not change between the three funds. “We do not compete with private capital. In fact, we are working with them to choose the ecosystem with them. Thus, our risks typically below 5%,” he said.

Among the other investors in Aragen, investment banking giant Goldman Sachs and a private capital company Quadria Capital, a health -oriented private capital company, invested $ 100 million with a value of about $ 1.4 billion in the company’s minority share. Chandra, “Appraisal with our investment is close to the previous round.” He said.

The first investment of the Avendus Future Leaders Fund to the health sector was in La Renon Healthcare in February. Avendus acquired a minority share in the company. La160 Crore.

FLF III Closing

Avendus runs three future leaders. I became a FLF La350 Crore, FLF II and FLF III both La1,500 CRORE, the latter has a Greenhoe option for someone else La1,500 crore. The fund reached the first end La850 crore in January and now La1,500 CRORE TARGET.

“Given the interest from our investors, we will use the Greenhoe option, C Chandra said. So far, 21% of FLF III capital has been placed and planned for the next two and a half years to reduce exposure to economic cycles.

Avendus has an important market share in the country’s technology and starting sectors. In fact, the company’s consultation work helped the country’s unicorn horses through early and late stage financing cycles. In 2022, the company started consultancy services for the companies planning the first public offers (IPO).

Out of Juspay

Avendus partially released from Juspay Technologies, a payment editorial and solution provider. The fund first invested in Juspay from FLF I in 2022 and then from FLF II.

“We have returned 1.5 times the capital to our investors. We sold our position in Juspay from FLF I and continued to protect our position in Juspay from FLF II. When Avendus Flf collected the company’s shares to Kedaara Capital and collected the D Series of 60 million dollars, he was in his investment in Juspay earlier this year.